EUVIMEDEUVIMED entdecken
Crossref

Evaluation of Response and Toxicity of Pemetrexed-Carboplatin Versus Paclitaxel-Carboplatin as First-Line Treatment in Metastatic NSCLC

Uday Sarkar, Sarwar Alam, Syed Hoque, Newton Sarker, Mohammad Ullah, Subarna Das, Tasnim Mahmud, Safayet Hossain

International Journal of Clinical Oncology and Cancer Research · 28.03.2025 · 10 (2) · 51-58

DOI: 10.11648/j.ijcocr.20251002.12 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Clinical Oncology and Cancer Research, online erschienen am 28.03.2025. Verfasst von Uday Sarkar und 7 weiteren Autor:innen. Die Arbeit nennt 15 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Non-small cell lung cancer (NSCLC) accounts for 80-85% of all lung cancer approximately. The paclitaxel-carboplatin combination is the established standard regimen of choice in metastatic NSCLC. Pemetrexed, a folate antimetabolite is also effective against non-small cell lung cancer. To compare the response and toxicity of the Pemetrexed-Carboplatin regimen with Paclitaxel-Carboplatin in the treatment of metastatic NSCLC. This Quasi-experimental study was conducted from three centers of Dhaka city. 80 patients (40 patients on each arm) who met the inclusion criteria of the study were enrolled. Arm-A received 500mg/m 2 Pemetrexed (Day 1) plus Carboplatin; AUC=5 (Day 1) IV, in another arm, 175mg/m 2 Paclitaxel (Day 1) plus Carboplatin AUC=6; (Day 1) IV, dexamethasone was given 12 mg on night before and on the morning of chemotherapy of each cycle & repeated every 21 days for 6 cycles; were given. Both outcome and toxicities were evaluated. Regarding the tumor control, there was no statistically significant difference in both arms at the follow-up after 6 weeks of completion of chemotherapy [Partial response was seen in 24 (60.00%) patients in Arm-A and in 22 (55.00%) patients in Arm-B, p = 0.58]. Grade ≥3 neutropenia was seen in 09 (22.50%) patients of the Arm-A and 20 (50.00%) patients of Arm-B, p

Zitieren

APA

Sarkar, U., Alam, S., Hoque, S., Sarker, N., Ullah, M., Das, S., Mahmud, T., & Hossain, S. (2025). Evaluation of Response and Toxicity of Pemetrexed-Carboplatin Versus Paclitaxel-Carboplatin as First-Line Treatment in Metastatic NSCLC. International Journal of Clinical Oncology and Cancer Research, 10(2), 51-58. https://doi.org/10.11648/j.ijcocr.20251002.12

Vancouver

Sarkar U, Alam S, Hoque S, Sarker N, Ullah M, Das S, et al. Evaluation of Response and Toxicity of Pemetrexed-Carboplatin Versus Paclitaxel-Carboplatin as First-Line Treatment in Metastatic NSCLC. International Journal of Clinical Oncology and Cancer Research. 2025;10(2):51-58. doi:10.11648/j.ijcocr.20251002.12

BibTeX
@article{Sarkar2025,
  author = {Sarkar, Uday and Alam, Sarwar and Hoque, Syed and Sarker, Newton and Ullah, Mohammad and Das, Subarna and Mahmud, Tasnim and Hossain, Safayet},
  title = {Evaluation of Response and Toxicity of Pemetrexed-Carboplatin Versus Paclitaxel-Carboplatin as First-Line Treatment in Metastatic NSCLC},
  journal = {International Journal of Clinical Oncology and Cancer Research},
  year = {2025},
  volume = {10},
  number = {2},
  pages = {51--58},
  doi = {10.11648/j.ijcocr.20251002.12}
}
Kostenlos starten →